Skip to main content
. 2019 May 24;5:JGO.18.00173. doi: 10.1200/JGO.18.00173

FIG 1.

FIG 1

Investigator-assessed progression-free survival in Asian and non-Asian patients (intention-to-treat population) at the data cutoff dates of (A) February 26, 2016, and (B) May 31, 2017. HR, hazard ratio; LET, letrozole; NE, not estimable; PAL, palbociclib; PCB, placebo.